Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma

Duke University

Status: Completed

Conditions: Multiple Myeloma

Treatments: Drug: Blenrep

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT05986682

218855 (Other Grant/Funding Number)

Pro00110976

Details and patient eligibility

About

The purpose of this study is to describe the real-world use of Belantamab Mafodotin - blmf (BLENREP) and associated patterns of care, including dosing and dose modification, eye care specialist visits, associated healthcare utilization, and clinical outcomes in patients with relapsed and/or refractory multiple myeloma (RRMM) seen in the Duke Cancer Institute (DCI) clinics.

Enrollment: 30 patients

Sex: All

Ages: 18 to 89 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18 years of age as of start of treatment with BLENREP
• Patients with a corresponding diagnosis code consistent with multiple myeloma seen at Duke.
• Patients with a record of starting treatment with BLENREP for RRMM between August 5, 2020 and November 22, 2022.
• Patients having healthcare encounters at Duke Cancer Institute (DCI) for at least 1-month after start of Blenrep treatment.

Exclusion criteria

• Patients who were included in any clinical trial for BLENREP including expanded access clinical trials
• Age > 89 years of age as of start of index therapy

Trial design